Aerovate Therapeutics Holds Shareholder Vote

Ticker: JBIO · Form: 8-K · Filed: Jun 7, 2024 · CIK: 1798749

Sentiment: neutral

Topics: shareholder-meeting, corporate-governance

TL;DR

Aerovate held a shareholder vote on June 5th, details to follow.

AI Summary

Aerovate Therapeutics, Inc. filed an 8-K on June 7, 2024, reporting on a meeting held on June 5, 2024, where security holders voted on certain matters. The filing does not disclose the specific proposals voted on or the outcomes of the vote.

Why It Matters

This filing indicates a shareholder meeting took place, which could involve significant corporate decisions or changes. Investors should look for subsequent filings to understand the outcomes of the vote.

Risk Assessment

Risk Level: low — The filing is a routine disclosure of a shareholder meeting and does not contain immediate financial or operational news.

Key Players & Entities

FAQ

What specific matters were submitted for a vote by Aerovate Therapeutics' security holders?

The filing does not specify the exact proposals voted on during the June 5, 2024 meeting.

What was the outcome of the shareholder vote on June 5, 2024?

The filing does not disclose the results or outcomes of the matters voted upon.

When was the shareholder meeting held?

The earliest event reported, which includes the submission of matters to a vote, occurred on June 5, 2024.

What is the principal executive office address for Aerovate Therapeutics, Inc.?

The principal executive offices are located at 930 Winter Street, Suite M-500, Waltham, Massachusetts 02451.

What is Aerovate Therapeutics, Inc.'s IRS Employer Identification Number?

Aerovate Therapeutics, Inc.'s IRS Employer Identification Number is 83-1377888.

Filing Stats: 647 words · 3 min read · ~2 pages · Grade level 10.6 · Accepted 2024-06-07 17:00:46

Key Financial Figures

Filing Documents

07 Submission of Matters to a Vote of Security Holders

Item 5.07 Submission of Matters to a Vote of Security Holders. Aerovate Therapeutics, Inc. (the "Company") held its 2024 Annual Meeting of Stockholders (the "Annual Meeting") on June 5, 2024. As of April 12, 2024, the record date for the Annual Meeting, there were 28,737,381 shares of the Company's common stock outstanding and entitled to vote at the Annual Meeting. The Company's stockholders voted on the following matters, which are described in detail in the Company's Definitive Proxy Statement filed with the U.S. Securities and Exchange Commission on April 26, 2024: (i) to elect each of David Grayzel, M.D. and Maha Katabi, Ph.D. as a Class III member of the board of directors, to serve until the Company's 2027 Annual Meeting of Stockholders and until his or her successor is duly elected and qualified ("Proposal 1"), and (ii) to ratify the selection of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024 ("Proposal 2"). Proposal 1 - Election of Class III Director Nominees The Company's stockholders approved the Class III director nominees recommended for election in Proposal 1 at the Annual Meeting. The results of Proposal 1 were as follows: Class II Director Nominee Votes For Votes Withheld Broker Non-Votes David Grayzel, M.D. 24,399,034 1,489,651 2,185,964 Maha Katabi, Ph.D. 25,853,289 37,357 2,184,003 Proposal 2 - Ratification of Appointment of the Company's Independent Registered Public Accounting Firm The Company's stockholders ratified the selection of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024. The results of Proposal 2 were as follows: For Against Abstain 28,074,033 511 105 No other matters were submitted to or voted on by the Company's stockholders at the Annual Meeting. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing